Form 8-K - Current report:
SEC Accession No. 0001193125-21-336740
Filing Date
2021-11-22
Accepted
2021-11-22 16:01:03
Documents
12
Period of Report
2021-11-22
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d241227d8k.htm   iXBRL 8-K 23707
  Complete submission text file 0001193125-21-336740.txt   148748

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA elym-20211122.xsd EX-101.SCH 2877
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE elym-20211122_lab.xml EX-101.LAB 18888
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elym-20211122_pre.xml EX-101.PRE 11850
5 EXTRACTED XBRL INSTANCE DOCUMENT d241227d8k_htm.xml XML 3486
Mailing Address 23515 NE NOVELTY HILL ROAD SUITE B221 #125 REDMOND WA 98053
Business Address 23515 NE NOVELTY HILL ROAD SUITE B221 #125 REDMOND WA 98053 425-276-2300
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

EIN.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40708 | Film No.: 211432487
SIC: 2834 Pharmaceutical Preparations